The tweet was deleted by the author.
But we saved everything 🙂.
Lexicon Pharmaceuticals is set to present new data regarding their investigational SGLT1/2 inhibitor at the American Heart Association's Scientific Sessions this weekend.
The focus of the presentation will be the inhibitor's effect in reducing major cardiovascular events, marking a significant advancement in cardiovascular health research. This new data could have profound implications for the development of future treatments aimed at mitigating cardiovascular risks. Lexicon is leveraging this research to potentially enhance therapeutic strategies for patients suffering from heart-related conditions.